What Do We Know So Far about Ofatumumab for Relapsing Multiple Sclerosis? A Meta-Analytical Study

Hafiza Munazza Taj; Maryam Talib; Sania Siddiqa; Azza Sarfraz; Zouina Sarfraz; Karla Robles-Velasco; Ivan Cherrez-Ojeda

doi:10.3390/healthcare10112199

What Do We Know So Far about Ofatumumab for Relapsing Multiple Sclerosis? A Meta-Analytical Study

Hafiza Munazza Taj
, Maryam Talib
, Sania Siddiqa
, Azza Sarfraz
, Zouina Sarfraz
, Karla Robles-Velasco
, Ivan Cherrez-Ojeda

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Ofatumumab is a monoclonal antibody that reduces the level of B cells that alter the progression of relapsing multiple sclerosis. Originally approved by the Food and Drug Administration (FDA) in August 2020, this meta-analysis determines the outcomes of four randomized controlled trials (RCTs) for endline outcomes of Gadolinium-enhancing T1 lesions on MRI scans reported as Cohen’s d and relapse rate reported as risk ratio. All four RCTs reported favorable findings of gadolinium-enhancing T1 lesions (Cohen’s d = −0.44, p < 0.00001). The relapse rate was reduced by 46% post ofatumumab administration (RR = 0.54, p < 0.00001). With 14 ongoing trials in this area, more data is required to consolidate our findings.

Original language	English
Article number	2199
Journal	Healthcare (Switzerland)
Volume	10
Issue number	11
DOIs	https://doi.org/10.3390/healthcare10112199
State	Published - Nov 2022

Keywords

B cells
clinical trials
meta analysis
neurodegeneration
ofatumumab
relapsing multiple sclerosis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/healthcare10112199

Cite this

@article{b1c16048007c40ae81e21c73c789c9c1,

title = "What Do We Know So Far about Ofatumumab for Relapsing Multiple Sclerosis? A Meta-Analytical Study",

abstract = "Ofatumumab is a monoclonal antibody that reduces the level of B cells that alter the progression of relapsing multiple sclerosis. Originally approved by the Food and Drug Administration (FDA) in August 2020, this meta-analysis determines the outcomes of four randomized controlled trials (RCTs) for endline outcomes of Gadolinium-enhancing T1 lesions on MRI scans reported as Cohen{\textquoteright}s d and relapse rate reported as risk ratio. All four RCTs reported favorable findings of gadolinium-enhancing T1 lesions (Cohen{\textquoteright}s d = −0.44, p < 0.00001). The relapse rate was reduced by 46\% post ofatumumab administration (RR = 0.54, p < 0.00001). With 14 ongoing trials in this area, more data is required to consolidate our findings.",

keywords = "B cells, clinical trials, meta analysis, neurodegeneration, ofatumumab, relapsing multiple sclerosis",

author = "Taj, \{Hafiza Munazza\} and Maryam Talib and Sania Siddiqa and Azza Sarfraz and Zouina Sarfraz and Karla Robles-Velasco and Ivan Cherrez-Ojeda",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors.",

year = "2022",

month = nov,

doi = "10.3390/healthcare10112199",

language = "Ingl{\'e}s",

volume = "10",

journal = "Healthcare (Switzerland)",

issn = "2227-9032",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "11",

}

TY - JOUR

T1 - What Do We Know So Far about Ofatumumab for Relapsing Multiple Sclerosis? A Meta-Analytical Study

AU - Taj, Hafiza Munazza

AU - Talib, Maryam

AU - Siddiqa, Sania

AU - Sarfraz, Azza

AU - Sarfraz, Zouina

AU - Robles-Velasco, Karla

AU - Cherrez-Ojeda, Ivan

PY - 2022/11

Y1 - 2022/11

N2 - Ofatumumab is a monoclonal antibody that reduces the level of B cells that alter the progression of relapsing multiple sclerosis. Originally approved by the Food and Drug Administration (FDA) in August 2020, this meta-analysis determines the outcomes of four randomized controlled trials (RCTs) for endline outcomes of Gadolinium-enhancing T1 lesions on MRI scans reported as Cohen’s d and relapse rate reported as risk ratio. All four RCTs reported favorable findings of gadolinium-enhancing T1 lesions (Cohen’s d = −0.44, p < 0.00001). The relapse rate was reduced by 46% post ofatumumab administration (RR = 0.54, p < 0.00001). With 14 ongoing trials in this area, more data is required to consolidate our findings.

AB - Ofatumumab is a monoclonal antibody that reduces the level of B cells that alter the progression of relapsing multiple sclerosis. Originally approved by the Food and Drug Administration (FDA) in August 2020, this meta-analysis determines the outcomes of four randomized controlled trials (RCTs) for endline outcomes of Gadolinium-enhancing T1 lesions on MRI scans reported as Cohen’s d and relapse rate reported as risk ratio. All four RCTs reported favorable findings of gadolinium-enhancing T1 lesions (Cohen’s d = −0.44, p < 0.00001). The relapse rate was reduced by 46% post ofatumumab administration (RR = 0.54, p < 0.00001). With 14 ongoing trials in this area, more data is required to consolidate our findings.

KW - B cells

KW - clinical trials

KW - meta analysis

KW - neurodegeneration

KW - ofatumumab

KW - relapsing multiple sclerosis

UR - https://www.scopus.com/pages/publications/85141719909

U2 - 10.3390/healthcare10112199

DO - 10.3390/healthcare10112199

M3 - Artículo

AN - SCOPUS:85141719909

SN - 2227-9032

VL - 10

JO - Healthcare (Switzerland)

JF - Healthcare (Switzerland)

IS - 11

M1 - 2199

ER -

What Do We Know So Far about Ofatumumab for Relapsing Multiple Sclerosis? A Meta-Analytical Study

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this